Well, of course I don’t know the reason, but as Chuck Carnevale – co-founder of FASTgraphs and known as Mr. Valuation – would say: price follows earnings.
This seems roughly true for RB as well over long enough time frames (see FASTgraphs above). Earnings for RB have dropped last year and are expected to drop again this year and price has seemingly already followed?
Earnings are expected to grow again next year and afterwards and I would expect price to follow (up) again, eventually.
No prediction of course as sometimes it takes more than one or two years for price to follow earnings, as e.g. everyone buying Altria in the past six years or so would have to admit.*
While waiting for Altria's price to follow its earnings, you can console yourself with that dividend cash flowing in ... at least that's what I am doing. :-)
I personally like to invest in …CHDVD. That’s the lazy way of investing in dividends
I am tempted to use my PF credits to buy some swiss insurance stocks though. As a waaaaay generalistic reason I’m not afraid of the impeding loom (global warming, wars etc) since 99.99% of the time insurances don’t pay that kind of risk.
Will be interesting to see if there’ll be a sector rotation (towards div yield stocks) happening given lower interest rates coming and tech stocks valuations being so high.
" Convincing plan to unlock value
Drastic portfolio reshuffle to give rise to a compelling reliable compounder
Yesterday, Reckitt took the opportunity of its H1 results to introduce a new ambitious
strategy which should drive a drastic reshaping of the company’s portfolio over coming
years. Reckitt’s plan effectively means that 29% of the group’s turn over is now under
strategic review with the group looking to divest £1.9bn of non core Hygiene revenues
(13% of sales) by the end of 2025 and “considering all strategic options” for its Mead
Johnson Nutrition operations (16% of sales). The remaining business (“new Reckitt”)
should have a compelling - clearly top quartile, earnings growth model (see here) owing
to: a) its above industry average LFL sales growth (7% LFL between 2018-23); b) simpler
& more agile structure (11 PowerBrands generating more than 80% of sales, new
organization); c) elevated gross margin (61%) and operating margin (>24%) both well
ahead of US peers; d) a fixed cost optimisation program which should yield £450m in
savings over the next 3.5 years and allow higher investments and offset any potential
dis-synergies arising from future asset disposals; and e) management commitment to
“returning surplus cash to shareholders, including excess proceeds from future
transactions” - while also signalling the low likelihood of medium to large size deals.
Short term benefit: current valuation anomaly finally addressed
We would acknowledge that Reckitt’s new plan will take time before being fully
completed and comes with several areas of risks and uncertainties - including the
potential disruptions caused by the portfolio and organisation reshuffle as well as the
value of the Essential Home and Mead Johnson Nutrition businesses. That said, the main
merit of yesterday’s announcement is that it is actively addressing Reckitt’s depressed
valuation by forcing the market to look at its sum of the parts (SOTP); indeed, our own
SOTP, which bakes in quite conservative assumptions for the non core assets, evidences
an unwarranted and exaggerated discount for new Reckitt relative to peers (see here).
Tornado impact reducing 2024 EPS by 1% but 2025 EPS unchanged
We have lowered our 2024 LFL sales growth forecast to +1.6% (vs. company’s guidance
of +1% to +3%) chiefly due to our more cautious forecast for Nutrition (-10% for FY24)
as a recent tornado has considerably disrupted the business’ supply chain - and will likely
shave off £150m of the group’s sales in Q3. For Health & Hygiene, we model +3.9% LFL
(was 4.5% previously) on account of slightly more intense promotional activities than
initially anticipated. Our FY24 margin forecast remains unchanged at 23.4% (+30bps
yoy). All in all, our 2024E EPS comes down by 1% to 321p but our FY25E EPS remains
unchanged at 362p. PT unchanged as a result.
Valuation: Shares on 12x 2025E P/E, a c50% discount to US peers"
Why not look just choose from the dividend aristocrats list? I used to work for one and had RSUs, it was nice seeing the dividend come in Dividend Aristocrats | Nasdaq
Anyone experienced with getting the Quellensteuer back from some of those European dividend payers?
I’ve recently become interested in some French and German ones, but it seems like it’s a pain in the butt to get the tax at source back even with Switzerland having tax treaties in place with those countries.
I sent my first request to get back taxes from Sweden. I might get news in the next months. I hope it goes well as I have now 6 swedish companies. For the french tax, I haven’t even try, but I only have 1 company.
Reckitt stock surges after US jury rejects claims against infant formula
Shares in Reckitt jumped 10 per cent on Friday after a US jury rejected claims that one of its infant formulas caused life-long injuries in a baby, the first positive outcome for the group in what has become a widespread litigation.
The claimants in St Louis, Missouri, were seeking $6bn of damages from Reckitt and US formula maker Abbott, in a rare joint trial of two corporate giants. Four further trials brought by parents of premature infants are scheduled for next year.
Shares in the London-listed consumer goods group fell to a decade low this year after two separate juries found against Reckitt and Abbott.
Reckitt is seeking to sell its US formula business, Mead Johnson, in a wide-ranging restructure.
By reading and partipating to this forum, you confirm you have read and agree with the disclaimer presented on http://www.mustachianpost.com/
En lisant et participant à ce forum, tu confirmes avoir lu et être d'accord avec l'avis de dégagement de responsabilité présenté sur http://www.mustachianpost.com/fr/
Durch das Lesen und die Teilnahme an diesem Forum bestätigst du, dass du den auf http://www.mustachianpost.com/de/ dargestellten Haftungsausschluss gelesen hast und damit einverstanden bist.
)